Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Sponsor

Peking University Cancer Hospital & Institute (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05512481

Collaborator

(none)

Enrollment

Arm

39.7

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.

Condition or Disease	Intervention/Treatment	Phase
Melanoma Acral Melanoma Temozolomide Apatinib Camrelizumab Neoadjuvant Pathological Response	Drug: Camrelizumab	Phase 2

Detailed Description

Patients with resectable melanoma can benefit from neoadjuvant therapy, including improved surgical outcomes, precise management of patients based on neoadjuvant response, and analysis of resistance mechanisms through histological sections for subsequent treatment. At present, there have been a number of clinical trials exploring the effect of neoadjuvant regimens for melanoma, and some published results have shown that neoadjuvant therapy can lead to a higher pathological response rate, thereby improving the RFS of patients.

In the past, this site has carried out a clinical study of Camrelizumab combined with Apatinib and Temozolomide for first-line treatment of unresectable acral melanoma, with a high preliminary clinical response rate and safety. Based on this, this study intends to evaluate the neoadjuvant treatment of completely resectable melanoma with Camrelizumab combined with Apatinib and Temozolomide in patients with stage III and IIB, IIC high-risk melanoma. To comprehensively evaluate the short-term and long-term benefits of neoadjuvant therapy and provide an important reference for neoadjuvant treatment strategies in the acral melanoma population.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral Melanoma

Anticipated Study Start Date :

Sep 10, 2022

Anticipated Primary Completion Date :

Dec 31, 2024

Anticipated Study Completion Date :

Dec 31, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Neoadjuvant/adjuvant therapy Drug: Camrelizumab Drug: Apatinib mesylate Drug: Temozolomide Injection	Drug: Camrelizumab NEOADJUVANT: All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle； SURGERY: All participants will have melanoma surgery after 2 cycles of treatment ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year Other Names: Apatinib Temozolomide

Arm

Intervention/Treatment

Experimental: Neoadjuvant/adjuvant therapy

Drug: Camrelizumab Drug: Apatinib mesylate Drug: Temozolomide Injection

Drug: Camrelizumab

NEOADJUVANT: All participants will receive neoadjuvant therapy with combination of Camrelizumab、Apatinib and Temozolomide for 2 cycle； SURGERY: All participants will have melanoma surgery after 2 cycles of treatment ADJUVANT: Participants will receive Camrelizumab every 3 weeks for 1 year

Other Names:

Apatinib

Temozolomide

Outcome Measures

Primary Outcome Measures

Pathological response rate [Week 8-12]
The primary endpoint is the pathological response rate at surgery after neoadjuvant study treatment. The pathological response is categorised thus: Complete pathological response (pCR) - 0% viable tumour cells in the surgical specimen Near complete pathological response - (near pCR) - <10% viable tumour Partial pathological response (pPR) - 10%-50% viable tumour No pathological response (pNR) - >50% viable tumour

Secondary Outcome Measures

Objective Response Rate [Months 0-6]
Disease Response as assessed by RECIST 1.1 and mRECIST
Recurrence-free survival [1year,2year]
The proportion of patients with an histologically confirmed diagnosis of disease recurrence (local, regional, and distant), as detected by the patient, on physical examination or during imaging surveillance, or death from any cause.
Overall survival [10 years]
The proportion of participants deceased from any cause.
Safety and tolerability of neoadjuvant and adjuvant treatment and surgical procedures. [90 days from last dose of study treatment]
The proportion of patients with adverse events as described in CTCAE version 5.0
Patient reported quality of life [90 days from last dose of study treatment]
The individual, summary and composite scores obtained from the validated EUROQOL QLQ-C30 questionnaires.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

age:18-75 years, male or female.
Histopathologically confirmed acral melanoma (stage Ⅱ/Ⅲ).
Has not received any systematic anti-tumor drug treatment.
Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.
ECOG 0-1.
Adequate organ function.
Life expectancy of greater than 12 weeks.
Patient has given written informed consent.

Exclusion Criteria:

Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy.
Known history of hypersensitivity to any component of apatinib, temozolomide, Camrelizumab.
Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ);
Subjects with any active autoimmune disease or history of autoimmune disease
Patients with any unstable systemic disease, including but not limited to: serious infection, uncontrolled diabetes, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, myocardial infarction, congestive heart failure, serious cardiac arrhythmia requiring medication, hepatic, renal or metabolic disease;
Received a live vaccine within 4 weeks of the first dose of study medication.
Pregnancy or breast feeding.
Decision of unsuitableness by principal investigator or physician-in charge.